MedTrace Logo

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

NCT00720421 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2010-12-10

No results posted yet for this study

Summary

The purpose of the study is to determine the effects of the compound AZD7325 as compared to lorazepam on sleepiness, concentration and brain activity.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD7325

AZD7325 10 mg oral 2 capsules

DRUG

AZD7325

AZD7325 1 mg oral 2 capsules

DRUG

AZD7325

AZD7325 Placebo oral 2 capsules

DRUG

Lorazepam

Lorazepam 1 mg oral 2 tablets

DRUG

Lorazepam

Lorazepam Placebo oral 2 tablets

Sponsors & Collaborators

Principal Investigators

  • J.M.A. Van Gerven, MD, PhD · CHDR Leiden, the Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00720421 on ClinicalTrials.gov